Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.34 |
| ▸ | CA2 | P00918 | 10/20 | 0.34 |
| ▸ | CA12 | O43570 | 9/20 | 0.34 |
| ▸ | CA9 | Q16790 | 9/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21962564 | 0.83 | EDNRB (0.41) | CA1CA2CA12CA9CA4 | |
| SCHEMBL20692373 | 0.76 | L3MBTL1 (0.33) | — | |
| SCHEMBL5646084 | 0.75 | CA2 (0.55) | CA1CA2CA12CA9HSD17B2 | |
| SCHEMBL22013623 | 0.74 | HTT (0.37) | MEN1KMT2AHPGD | |
| SCHEMBL21962522 | 0.74 | HSD17B2 (0.38) | CA1CA2CA12CA9HSD17B2 | |
| SCHEMBL23569182 | 0.72 | LOX (0.33) | CA1CA2CA12CA9CA4 | |
| SCHEMBL21962325 | 0.71 | LOXL2 (0.34) | CA1CA2CA12CA9NPSR1 | |
| SCHEMBL22012924 | 0.70 | LOX (0.35) | CA2 | |
| SCHEMBL29114229 | 0.69 | — | — | |
| SCHEMBL21722661 | 0.69 | CA1 (0.42) | CA1CA2CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CA1 3732/4885CA2 1210/4885CA12 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.